10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
ICU Medical's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was -0.63%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ICU Medical's 10-Year ROIIC % or its related term are showing as below:
ICUI's 10-Year ROIIC % is ranked worse than 53.13% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.54
vs ICUI: -0.63
ICU Medical 10-Year ROIIC % Historical Data
The historical data trend for ICU Medical's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ICU Medical's 10-Year ROIIC %
For the Medical Instruments & Supplies subindustry, ICU Medical's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical's 10-Year ROIIC % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ICU Medical's 10-Year ROIIC % falls into.
ICU Medical 10-Year ROIIC % Calculation
ICU Medical's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ICU Medical (NAS:ICUI) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ICU Medical 10-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of ICU Medical's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
ICU Medical is a California-based, pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017, and Smiths Medical from Smiths Group in 2022. It holds top-tier positions in its original reporting segments: infusion consumables (25% of 2022 revenue), IV solutions (16%), infusion systems (15%), and critical care (2%) as well as its new Smiths segments: Smiths infusion systems (15%), vascular access (14%), and vital care (12%). The combined entity remains primarily U.S. focused, generating over 64% of its sales domestically.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICUI has been successfully added to your 